Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

LEUVEN, Belgium, August 27 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

During 2009, ThromboGenics has continued to focus on the activities which are key to its aim of becoming a profitable, integrated company focused on cutting edge ophthalmic medicines. Central to this plan is the Company's lead product, microplasmin, which is in Phase III trials for the treatment of back of the eye disease. Patient recruitment in this Phase III program is running smoothly and the Company expects to report the first results from these studies by mid 2010.

The clinical development of the Company's unique long-acting anticoagulant TB-402, which is in Phase II trials for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery, has progressed more rapidly than originally expected.

Patrik De Haes, CEO of ThromboGenics, said:

"ThromboGenics has seen most of its key programs make significant progress during the course of 2009. We are very happy with the speed of patient recruitment in the microplasmin Phase III program. Microplasmin is central to our aim of building a strong, profitable and integrated company centered on cutting edge ophthalmic medicines. Given our increasing confidence in the clinical merits of microplasmin we are now starting to develop our commercialization plans for this novel product. We are also very encouraged by the progress of the Phase II program for TB-402, as recruitment is ahead of schedule. This clinical study has reinforced our view that we have an attractive out-licensing opportunity for companies keen to enhance their position in the anti-coagulant therapy market. Our partnership with
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
(Date:12/24/2014)... GMO corn cases filed across the United ... process of being consolidated in a Kansas federal court for ... MIR 162 Corn Litigation, MDL No. 2591 in the U.S. ... the Syngenta GMO corn multidistrict litigation (MDL) has been handed ...
(Date:12/24/2014)... December 23, 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide continued ... upgrades. This webinar series demonstrates online communication features ... leverage web conferencing’s most innovative and powerful tools. ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... 2012  Tarsa Therapeutics, Inc. today announced completion of ... by new investor Foresite Capital.  James Tananbaum, MD, ... of Directors.  Tarsa,s existing venture capital investors—Novo A/S, ... in the new financing round.  ...
... GAITHERSBURG, Md., March 15, 2012 Today GenVec, Inc. (NASDAQ: ... quarter and year ended December 31, 2011.  For the year ... of $7.4 million, or $0.58 per share, compared with a ... the year ended December 31, 2010. GenVec ended the year ...
... global carbon market requires substantial reform because it too often ... to help, according to new research from the Economic and ... released as the UN, which has designated 2012 the International ... about its Clean Development Mechanism (CDM), under which companies are ...
Cached Biology Technology:Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 3Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 4GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 2GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 3GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 4GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 5GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 6UN emission market needs urgent reform 2
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 The ... it easier to detect and prevent counterfeit microcircuits from ... agency started performing an in-house microcircuit anti-counterfeit initiative dubbed ... purchased microcircuits while increasing their reliability throughout the supply ...
(Date:12/15/2014)... Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced the ... report to their offering. ... technology used for the identification of individuals. Facial recognition ... such as nose, jaw edges, mouth, and the distance ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Colo. Iowa State University, ConocoPhillips and the ... (NREL) have reached a Memorandum of Understanding to ... near, mid- and long-term. The collaboration will bring ... the most efficient and cost-effective methods for making ...
... 2008 - Biofuels are widely considered one of the ... and environmentalists alike. However, unless principles and standards for ... severe environmental impacts and reduce biodiversity the very ... currently the most widely used biofuel in the United ...
... neurologist on faculty in the Virginia-Maryland Regional College ... has been awarded funding from the Wake Forest ... for treating brain tumors in dogs, cats and ... in the Department of Small Animal Clinical Sciences ...
Cached Biology News:Iowa State, ConocoPhillips and National Renewable Energy Lab to cooperate on biofuels research 2Study finds concerns with biofuels 2Veterinary college researcher studying brain tumors in people and animals 2Veterinary college researcher studying brain tumors in people and animals 3
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: